Results 321 to 330 of about 2,418,369 (395)
Risk Factors for Recurrence in Serous Borderline Ovarian Tumors and Early-Stage Low-Grade Serous Ovarian Carcinoma. [PDF]
Zhang J, Wang M, Wu Y.
europepmc +1 more source
This study presents a novel implantable drug delivery systemwith a biodegradable poly(caprolactone) membrane and compressed drug core forsustained release. These implantable devices deliver risperidone in vitro for 170 days and in vivo for 49 days in rats, showing promise for chronic conditions like schizophrenia.
Linlin Li+9 more
wiley +1 more source
NeoCast is a next‐generation, solvent‐free, non‐adhesive liquid embolic designed for indications where deep occlusion is desired (e.g., tumors and chronic subdural hematoma). This novel agent offers ideal embolic properties: injectability, controllability, excellent visibility, and biocompatibility.
Quynh P. Pham+16 more
wiley +1 more source
Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study. [PDF]
Renaud S+8 more
europepmc +1 more source
DexaPatch, an implantable, low‐swelling amphiphilic hydrogel system containing dexamethasone‐PLGA microparticles, is developed and characterized for sustained local steroid release to reduce postoperative inflammation in tight surgical spaces. DexaPatch significantly reduces postoperative edema and fibrosis in a rabbit model of anterior spinal surgery,
Stephen W. Linderman+6 more
wiley +1 more source
Correlation Between PhenoAgeAccel and Clinical Outcomes in Atrial Fibrillation Patients Undergoing Radiofrequency Catheter Ablation. [PDF]
Zhao Z+5 more
europepmc +1 more source
Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy
The review summarizes the synthesis of mesoporous silica nanoparticles (MSNs) with modifiable surface properties, functionalization strategies, mechanism of therapeutic payload release, and current applications in gene therapy, focusing on their capabilities in the targeted delivery of therapeutic nucleic acids, CRISPR‐Cas systems, and other genetic ...
Tamanna Binte Huq+4 more
wiley +1 more source
A dual‐functional hafnium oxide nanoplatform is developed for enhanced cancer radiotherapy. This innovative system combines the inherent radiosensitizing properties of high‐Z hafnium oxide with Bcl‐2 gene‐silencing capabilities. The nanoplatform demonstrated synergistic enhancement of radiotherapy efficacy through increased generation of reactive ...
Seungyong Shin+12 more
wiley +1 more source